Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
61 hedge funds and large institutions have $105M invested in Taro Pharmaceutical Industries Ltd. in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 19 increasing their positions, 19 reducing their positions, and 15 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 19
14% less funds holding
Funds holding: 71 → 61 (-10)
19% less capital invested
Capital invested by funds: $130M → $105M (-$25M)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.84M |
| 2 |
CAC
Cowen and Company
New York
|
+$2.09M |
| 3 |
KAM
Krensavage Asset Management
New York
|
+$1.89M |
| 4 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$1.21M |
| 5 |
SFO
Stokes Family Office
New Orleans,
Louisiana
|
+$314K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$7.36M |
| 2 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$2.06M |
| 3 |
Renaissance Technologies
New York
|
-$1.04M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.02M |
| 5 |
Millennium Management
New York
|
-$386K |
TARO Hedge Fund Activity: Q4 2022 in Review
61 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q4 2022, worth a combined $105M — down 19% from $130M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TARO and 8 opened new positions — a net loss of 7 holders — while 19 trimmed existing stakes and 19 added.
The largest buyer was Ameriprise, adding an estimated $2.84M. The largest seller was Armistice Capital, exiting entirely with an estimated $7.36M sold.
- 61 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q4 2022, down from 71 in Q3 2022.
- Funds reported $105M of Taro Pharmaceutical Industries Ltd. stock for Q4 2022, down 19% quarter-over-quarter.
- 8 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q4 2022 and 15 closed out, a net change of -7 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q4 2022 was Ameriprise, an estimated $2.84M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q4 2022 was Armistice Capital, an estimated $7.36M sold.
Based on aggregated 13F filings for Q4 2022.